2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 240

Finger Joint Cartilage Thickness Evaluated By Semiquantitative Ultrasound Score in Patients with Rheumatoid Arthritis
Abstract Number: 2012

First Description of Tenosynovitis Prevalence in a Large Cohort of ACPA-Positive Patients
Abstract Number: 1541

First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Abstract Number: 907

Five-Year Evolution of the Center of Excellence in Musculoskeletal Care and Education: A National Resource for the Continuum of Health Professions Education and Scholarship
Abstract Number: 1471

Flare Incidence and Predictive Factors in a Population of Patients with Rheumatoid Arthritis Under Optimised Treatment with Adalimumab and Infliximab
Abstract Number: 445

FLARE-RA Instrument Detects RA Flares Independent of Disease Activity
Abstract Number: 1374

Flares in Patients with Rheumatoid Arthritis Are Strongly Associated with Worse Clinical Outcomes but Are Difficult to Predict
Abstract Number: 2062

Flow-Mediated Dilation As a Marker of Endothelial Dysfunction in Gout
Abstract Number: 111

Focused Musculoskeletal Ultrasound Teaching: Effect on Medical Students’ Physical Examination Skills
Abstract Number: 1700

Focusing on Pulmonary Vascular Disease at Early Stage of Systemic Sclerosis: Exercise-Induced Pulmonary Arterial Hypertension and Gene Co-Expression Networks Involved in Its Pathogenesis
Abstract Number: 276

Follow-up of Patients with Musculoskeletal Manifestations Related to Chikungunya Fever
Abstract Number: 1375

Foot Arthritis : Poor Prognosis Factor in RA
Abstract Number: 2430

For Each HLA-DRB1 Genotype, the Likelihood to Develop RA Correlates with the Probability of Binding at Least a Peptide from PAD4
Abstract Number: 2749

Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries
Abstract Number: 2700

Fra-2 Overexpression Leads to Systemic Autoimmunity By Affecting IL2 Dependent Treg Homeostasis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].